抗环瓜氨酸化蛋白/肽抗体检测的标准化:新型候选参考品的评估
该国际研究用九种 commercial ACPA 检测法同时分析 NIBSC 候选标准品 18/204 与 IUIS-CDC ACPA 参考品,以及 398 例类风湿关节炎(RA)患者和 1073 例非 RA 个体的诊断样本。结果显示不同检测法间定量结果差异大,以 NIBSC 18/204 校准后多个检测法间 ACPA 结果对齐改善,并可对齐部分检测法的临床判读。作者认为采用国际标准高度可取,候选 NIBSC 18/204 标准品改善了多数 ACPA 检测法的标准化和对齐,或可推荐作为商业检测的参考品。
要点
- 不同商业 ACPA 检测法间定量结果差异大。
- 多数检测法中 IUIS-CDC 标准品值低于 NIBSC 18/204。
- 以 NIBSC 18/204 校准可改善多个检测法间结果对齐。
核心结论
- 采用 ACPA 测定的国际标准高度可取。
- 候选 NIBSC 18/204 标准品改善了多数 ACPA 检测法的标准化和对齐,或可推荐作为商业检测的参考品。
研究设计与样本
- 国际研究,用九种商业 ACPA 检测法同时分析 NIBSC 候选 ACPA 标准品 18/204 与 IUIS-CDC ACPA 参考品,以及 398 例 RA 患者和 1073 例非 RA 个体的诊断样本。
主要发现
- 对于两种参考品以及 RA 患者和非 RA 个体的样本,不同检测法间定量 ACPA 结果存在大差异。
- 多数检测法中 IUIS-CDC 标准品的值低于 NIBSC 18/204 的值,IUIS-CDC/NIBSC 比值在部分但非全部检测法中相当。
- 以 NIBSC 18/204 作为校准品时,所评估的多个检测法间 ACPA 结果的对齐获得改善。
- NIBSC 18/204 可使部分但非全部检测法的临床判读对齐。
临床怎么用
- 作者认为采用 ACPA 测定的国际标准高度可取。
- 作者认为候选 NIBSC 18/204 标准品改善了多数 ACPA 检测法的标准化和对齐,或可推荐作为商业检测的参考品。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Commercial assays measuring antibodies to citrullinated protein/peptide (ACPA) show poor quantitative agreement. The diagnostic industry has never adopted the International Union of Immunological Societies-Centers for Disease Control and Prevention (IUIS-CDC) ACPA reference standard. Recently, the National Institute for Biological Standards and Control (NIBSC) prepared a new candidate ACPA standard (18/204). We evaluated both reference materials using different commercially available ACPA assays. MATERIALS AND METHODS: This is an international study in which the NIBSC candidate ACPA standard and the IUIS-CDC ACPA reference material were analysed together with 398 diagnostic samples from individuals with rheumatoid arthritis (RA) and in 1073 individuals who did not have RA using nine commercial ACPA assays. RESULTS: For both reference materials and samples from individuals with RA and individuals who did not have RA, there were large differences in quantitative ACPA results between assays. For most assays, values for the IUIS-CDC standard were lower than values for NIBSC 18/204 and the IUIS-CDC/NIBSC ratio was comparable for several, but not all assays. When NIBSC 18/204 was used as a calibrator, an improvement in alignment of ACPA results across several of the evaluated assays was obtained. Moreover, NIBSC 18/204 could align clinical interpretation for some but not all assays. CONCLUSION: Adoption of an international standard for ACPA determination is highly desirable. The candidate NIBSC 18/204 standard improved the standardisation and alignment of most ACPA assays and might therefore be recommended to be used as reference in commercial assays.
引用
- Van Hoovels L, Studholme L, Vander Cruyssen B, et al. Standardisation of ACPA tests: evaluation of a new candidate reference preparation. Ann Rheum Dis. 2022. PMID: 35697487. doi:10.1136/annrheumdis-2021-221849
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。